4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene TherapyMarketBeat · 3 days ago
4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day TranscriptSeeking Alpha · 3 days ago
Reviewing GeoVax Labs (NASDAQ:GOVX) & 4D Molecular Therapeutics (NASDAQ:FDMT)Defense World · 4 days ago
4DMT Announces New Employment Inducement GrantsGlobeNewsWire · Oct 16, 2026
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Average Price Target of $28.90Defense World · Oct 13, 2026
4DMT to Host Investor Day on October 21, 2026GlobeNewsWire · Oct 5, 20264D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$1.02 | -$1.04 | Miss |
| May 7, 2026 | -$0.97 | -$1.01 | Miss |
| Mar 18, 2026 | -$0.53 | $0.43 | Beat |
| Nov 10, 2025 | -$1.02 | -$1.01 | Beat |
| Aug 11, 2025 | -$0.88 | -$0.98 | Miss |
| May 8, 2025 | -$0.84 | -$0.86 | Miss |